Research across Hypersensitivity, Immediate
Related studies from across the Hypersensitivity, Immediate family.
New HAE subtypes involving endothelial dysfunction support biomarker discovery and therapeutic strategies to stabilize the vascular barrier
New insights into hereditary angioedema mechanisms and treatment strategies
This review discusses implications for biomarker discovery and therapeutic strategies aimed at stabilizing the endothelial barrier in patien…
A review discusses how stabilizing the endothelial barrier could help treat hereditary angioedema, offering new therapeutic directions for p…
Probiotic co-administration with berotralstat improves GI tolerability in HAE patients
Probiotics may help manage side effects of HAE treatment
This pilot case series from six Italian centers evaluated probiotic co-administration with berotralstat in 25 adolescents and adults with he…
New early treatment steps for hereditary angioedema might reduce monthly attacks while keeping stomach issues to a minimum.
Lanadelumab reduced attacks in Chinese adults with hereditary angioedema over six months
Imagine waking up with severe swelling in your throat. It feels like you cannot breathe. This is what hereditary angioedema feels like for many people
This open-label study evaluated safety and efficacy of subcutaneous lanadelumab in patients with hereditary angioedema in China.
This rare condition causes painful swelling under the skin.
Oral deucrictibant reduced hereditary angioedema attack rates versus placebo in a phase 2 trial
Can a daily pill prevent painful swelling attacks for people with hereditary angioedema?
A phase 2 randomized trial in 34 adults with hereditary angioedema types 1 or 2 found that daily oral deucrictibant (20 mg or 40 mg) signifi…
A daily pill reduced painful hereditary angioedema attacks by 80% in adults taking it for 12 weeks, offering a new preventive option for thi…
Oral deucrictibant reduces hereditary angioedema attack severity in phase 2 crossover trial
Oral drug reduces hereditary angioedema attack severity in phase 2 trial
In a phase 2 randomized, double-blind, placebo-controlled crossover trial of 62 adults with hereditary angioedema, oral deucrictibant (10 mg…
A new oral drug reduced the severity of hereditary angioedema attacks compared to placebo, offering a convenient treatment option for painfu…